Evidence map›Paper›PMID 33573134›Full record

ArticleInternational journal of molecular sciences2021

Genetic Variants of

María Gaibar, Miguel Galán, Alicia Romero-Lorca, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander, Apolonia Novillo

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Association ofIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

María GaibarDepartment of Health Sciences, Health Sciences Faculty, European University of Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.
Miguel GalánDepartment of Health Sciences, Health Sciences Faculty, European University of Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.ORCID 0000-0002-6695-1509
Alicia Romero-LorcaDepartment of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.
Beatriz AntónDepartment of Oncology, University Hospital of Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain.
Diego MalónDepartment of Oncology, University Hospital of Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain.
Amalia MorenoDepartment of Pathological Anatomy, University Hospital of Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain.
Ana Fernández-SantanderDepartment of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.
Apolonia NovilloDepartment of Pre-Clinical Dentistry, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.

Funding

Foundation of the European University FGUE001804 and FGUE001805Universidad Europea de Madrid 2018/UEM25 and 2017/UEM04
6 · The paper itself

Abstract

Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) in 13 of these genes to predict tumour response and clinical outcome measured as progression free survival (PFS) and overall survival (OS) in 57 patients with metastatic colorectal cancer (mCRC) given bevacizumab plus chemotherapy. SNPs were detected (iPLEX® Assay) in genomic DNA extracted from formalin-fixed paraffin-embedded tumour specimens. The variant allele

Indexed as

AdultAgedAged, 80 and overAngiopoietin-1Antineoplastic Combined Chemotherapy ProtocolsApyraseBevacizumabBiomarkers, TumorBiopsyColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFibroblast Growth Factor 2HumansMaleMatrix Metalloproteinase 9Angiopoietin-1ANGPT1 protein, humanApyraseBevacizumabBiomarkers, TumorENTPD1 protein, humanFibroblast Growth Factor 2Matrix Metalloproteinase 9MMP9 protein, humanangiogenesisbevacizumabcolorectal cancerpolymorphisms

Identifiers

PMID33573134
PMCPMC7866547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.